In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Corp.

Division of Sanofi
www.genzyme.com

Latest From Genzyme Corp.

Rare Is The Definition Of Leadership: The Lasting Legacy Of Henri Termeer

In a recent interview, ProQR’s founder Daniel de Boer cited the enormous impact that fellow Dutch businessman Henri Termer played in getting his fledging biotech start-up off the ground – especially given the circumstances.  Some 10 years ago, the then twenty-something budding biotech entrepreneur crossed the Atlantic on a chance that Termeer would answer what amounted to an unscheduled desk-knock at the rare disease pioneer’s office at Genzyme HQ in Cambridge, MA.  He did – and the rest is history.

Leadership Strategy

The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight

How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.

C-Suite Speaks Gene Therapy

Wanted: Orphan Drugs, Antivirals Dominate China's Latest Fast Track List

Half of the newly selected imported drugs slated for fast track review in China are rare disease treatments, followed by antiviral drugs for influenza and HIV, reflecting key medical needs in the country.

Rare Diseases Review Pathway

EU Hat Trick For Bluebird’s Beta-Thalassemia Gene Therapy

bluebird bio is set to enter the EU market with the first gene therapy for transfusion-dependent β-thalassemia, after the European Medicines Agency reviewed its product in record time. Bluebird believes that the agency’s Priority Medicines (PRIME) and adaptive pathways programs have been instrumental in smoothing its path.

Drug Review Gene Therapy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register